Elon Musk confirmed this week that restoring sight is Neuralink's next major objective — not just for people who have lost their vision, but for individuals who have never seen at all. The announcement points to a device called Blindsight, a brain-computer interface that bypasses the eyes entirely. Here's what we know about how it works, where it stands, and what the road ahead looks like.
What exactly is Blindsight?
Blindsight is Neuralink's implantable chip designed specifically to restore vision. Unlike conventional treatments that work with the eye itself, Blindsight implants a microelectrode array directly into the visual cortex — the region of the brain that processes sight. An external camera captures the visual environment, AI translates that information into electrical signals, and those signals stimulate neurons in the cortex to create artificial visual perception. The eyes and optic nerves are bypassed entirely, which is why the device can potentially work even for people born blind.
Who is actually eligible for this?
The key requirement is an intact visual cortex. That means Blindsight is designed for people who are blind due to damaged or absent eyes, severed optic nerves, or congenital conditions — as long as the brain's visual processing center itself is functional. According to background research, Neuralink has already tested visual implants in monkeys, with one animal carrying a visual implant for approximately three years.
What will the initial vision actually look like?
Musk has been candid about the early limitations. The first generation of Blindsight vision will be low-resolution — his own comparison is "Atari graphics." Think pixelated shapes and basic spatial awareness rather than sharp, detailed sight. That said, the long-term roadmap is considerably more ambitious: Neuralink has stated the technology could eventually deliver vision that exceeds natural human sight, including the ability to perceive infrared, ultraviolet, or even radar wavelengths.
Where does Blindsight stand with regulators?
The U.S. Food and Drug Administration granted Blindsight a "Breakthrough Device Designation" in September 2024. This designation is reserved for devices that show potential to treat life-threatening or irreversibly debilitating conditions, and it accelerates the regulatory review process. It is not approval — but it is a meaningful signal that the FDA considers the underlying science credible enough to fast-track.
When and where will human trials begin?
Human clinical trials for Blindsight were expected to begin in late 2025 or early 2026, meaning they are either just getting underway or imminent as of this writing. The first human implant may take place in the United Arab Emirates, where Neuralink has a partnership with Cleveland Clinic Abu Dhabi. Neuralink also opened its global patient registry in April 2025 for people interested in participating in vision restoration and other studies. Separately, the company has joined a clinical collaboration with researchers at the University of California, Santa Barbara, focused on an AI-powered "Smart Bionic Eye" capable of assisting with facial recognition, reading, and navigation.
What will it cost?
Early estimates put the initial cost of a Blindsight implant above $100,000. That figure is consistent with how most first-generation medical devices are priced — high at launch, with significant reductions expected as manufacturing scales and the procedure becomes more routine. No official pricing has been announced by Neuralink.
How does this fit into Neuralink's broader work?
Neuralink's first human implant, focused on motor control for paralyzed patients, demonstrated that the core BCI technology works in a clinical setting. Blindsight represents the next frontier: applying that same direct brain-stimulation approach to the sensory side. If motor restoration proved the concept, vision restoration would prove the platform's versatility — and potentially open the door to other sensory applications down the line.
The ambition here is real, and so is the distance still to travel. Regulatory approval, surgical scalability, and long-term device reliability all remain open questions. But with FDA breakthrough status secured, animal testing behind it, and human trials beginning, Blindsight has moved well past the theoretical stage.
Sources & reporting notes
The links below identify the material source records used for this report.
- @elonmusk on X (2026-07-24T07:52:50.000Z) — Direct source
Source links are preserved as published or accessed. See our editorial standards and corrections policy.
The BASENOR Editorial Desk covers Tesla, SpaceX, and related technology, curating reporting from primary sources — official accounts, regulatory filings, and software release data. Every article passes source-record and fact-checking review before publication. About the newsroom.
This report was curated by the BASENOR Editorial Desk from the sources listed above. Read our editorial standards or email editorial@basenor.com to report an error.
